| Business Summary | | Axonyx
Inc.
is
engaged
in
the
business
of
acquiring
and
developing
novel
post-discovery
central
nervous
system
drug
candidates,
primarily
in
the
areas
of
memory
and
cognition.
As
of
year-end
2000,
the
Company
has
acquired
worldwide
exclusive
patent
rights
to
three
main
classes
of
therapeutic
compounds
designed
for
the
treatment
of
Alzheimer's
disease
(AD),
Mild
Cognitive
Impairment
(MCI)
and
related
diseases.
The
Company
has
also
acquired
patent
rights
to
a
fourth
class
of
potential
therapeutic
compounds
designed
for
the
treatment
of
prion-related
diseases.
The
Company
is
pursuing
two
different
types
of
products
for
the
treatment
of
AD.
These
AD-targeted
approaches
include
Phenserine,
a
novel,
long-acting
and
brain-directed
analog
of
the
classical
drug
physostigmine,
which
is
a
potent
inhibitor
of
acetylcholinesterase,
and
Phenethylnorcymserine,
a
butyrylcholinesterase
inhibitor. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Axonyx
Inc.
is
engaged
in
identifying
and
acquiring
novel
post-discovery
central
nervous
system
(CNS)
drug
candidates.
It
acquires
patent
rights
to
CNS
pharmaceutical
compounds
and
advances
the
compounds
through
clinical
development
toward
regualatory
approval.
For
the
six
months
ended
6/30/01,
revenues
fell
from
$104
thousand
to
$0.
Net
loss
rose
51%
to
$4.4
million.
Results
reflect
the
absence
of
license
fees
and
an
increase
in
clinical
trial
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Albert Angel, 63 Chairman | -- | Marvin Hausman, M.D., 59 Pres
and CEO | $340K | Gosse Bruinsma, M.D., 47 COO | -- | Michael Strage, 41 VP,
Treasurer, CAO, Director | 162K | Michael Espey, 39 VP,
Gen. Counsel, Sec., Director | 150K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|